AEON Biopharma Inc Sustainability Reports
A clinical-stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450, for the treatment of multiple debilitating medical conditions.
Sector: Manufacturing
Country: United States
Exchange: NYSE American
1 reports from 2023 to 2023
Company Profile
A clinical-stage biopharmaceutical company focused on developing its proprietary botulinum toxin complex, ABP-450, for the treatment of multiple debilitating medical conditions.
Reports
1 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
Years
